BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 7, 2012
View Archived Issues
New bacterial strain targets hypoxic regions of solid tumors
Read More
Mouse model of McArdle's disease created / News in Context
Read More
Takeda reviews highlights for first quarter of fiscal 2012
Read More
Capstone Therapeutics and LipimetiX enter joint venture
Read More
Novel fatty acid synthase inhibitors designed
Read More
Scientists develop new DGAT inhibitors
Read More
New antibiotics prepared in Portugal
Read More
Novel protein kinase inhibitors disclosed
Read More
TWi Pharmaceuticals reports phase IIb results on AC-201
Read More
Study identifies role of thrombomodulin-aPC pathway in radioprotection
Read More
Research at Bioenergenix yields novel PAS-kinase inhibitors
Read More
Antibody improves glycemia in first-in-human study
Read More
Dyax presents new plasma kallikrein-binding antibodies
Read More
Recruitment begins in phase Ib/IIa Declotana study
Read More
New vaccine approved in Japan for prevention of pertussis, diphtheria, tetanus and poliomyelitis
Read More
Rexahn completes exploratory RX-3117 study
Read More
Phase II Zybrestat combination study meets safety criteria
Read More
PharmaEngine and Nanobiotix enter license and collaboration agreement for radioenhancer
Read More
HIV drug prevents GVHD and preserves immune function in bone marrow transplant recipients
Read More
Pluristem gains clearance for PLX cell study in Germany
Read More
Phase III Alzheimer's disease program discontinued
Read More
Saladax and Bristol-Myers Squibb expand collaboration
Read More
Phase III trial in NSCLC does not meet primary endpoint
Read More
Novel PI3K-delta inhibitor discovered by researchers from Cellzome
Read More
Antisense Therapeutics prepares for phase II trial in acromegaly
Read More
Novacta Biosystems completes phase I study of oral treatment for CDI
Read More